222 related articles for article (PubMed ID: 15757425)
1. Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update.
Henry DH
Expert Opin Pharmacother; 2005 Feb; 6(2):295-310. PubMed ID: 15757425
[TBL] [Abstract][Full Text] [Related]
2. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
Henry DH
Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
[TBL] [Abstract][Full Text] [Related]
3. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.
Cheer SM; Wagstaff AJ
Drugs; 2004; 64(3):323-46. PubMed ID: 14871172
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of epoetin alfa in cancer therapy.
Henry DH
Oncologist; 2004; 9(1):97-107. PubMed ID: 14755019
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
[TBL] [Abstract][Full Text] [Related]
6. Managing cancer-related anaemia with epoetin alfa.
Itri LM
Nephrol Dial Transplant; 2002; 17 Suppl 1():73-7. PubMed ID: 11812917
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
[TBL] [Abstract][Full Text] [Related]
8. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
[TBL] [Abstract][Full Text] [Related]
9. The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety.
Itri LM
Semin Oncol; 2002 Jun; 29(3 Suppl 8):81-7. PubMed ID: 12082659
[TBL] [Abstract][Full Text] [Related]
10. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
11. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
Glaspy J; Bukowski R; Steinberg D; Taylor C; Tchekmedyian S; Vadhan-Raj S
J Clin Oncol; 1997 Mar; 15(3):1218-34. PubMed ID: 9060566
[TBL] [Abstract][Full Text] [Related]
12. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.
Campos SM; Duh MS; Lefebvre P; Rosberg J
J Natl Compr Canc Netw; 2005 Nov; 3(6):807-16. PubMed ID: 16316616
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
[TBL] [Abstract][Full Text] [Related]
14. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
15. Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins.
Oberhoff C
Support Care Cancer; 2007 Jun; 15(6):603-611. PubMed ID: 17277926
[TBL] [Abstract][Full Text] [Related]
16. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.
Fallowfield L; Gagnon D; Zagari M; Cella D; Bresnahan B; Littlewood TJ; McNulty P; Gorzegno G; Freund M;
Br J Cancer; 2002 Dec; 87(12):1341-53. PubMed ID: 12454760
[TBL] [Abstract][Full Text] [Related]
17. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
18. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
Patton J; Reeves T; Wallace J
Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
